FibroGen, Inc. (NASDAQ:FGEN - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for FibroGen in a research note issued to investors on Wednesday, April 3rd. William Blair analyst A. Hsieh forecasts that the biopharmaceutical company will earn $0.04 per share for the quarter. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for FibroGen's current full-year earnings is ($1.09) per share. William Blair also issued estimates for FibroGen's Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.23 EPS and Q4 2025 earnings at $0.26 EPS.
Separately, StockNews.com assumed coverage on FibroGen in a research report on Friday, December 8th. They set a "hold" rating on the stock. One research analyst has rated the stock with a sell rating and four have given a hold rating to the stock. Based on data from MarketBeat.com, FibroGen presently has an average rating of "Hold" and an average price target of $17.00.
Get Our Latest Report on FGEN
FibroGen Price Performance
NASDAQ:FGEN traded up $0.11 during mid-day trading on Thursday, hitting $1.58. The company's stock had a trading volume of 4,157,745 shares, compared to its average volume of 2,728,211. The business's fifty day moving average is $2.06 and its two-hundred day moving average is $1.16. The stock has a market cap of $156.06 million, a price-to-earnings ratio of -0.54 and a beta of 0.70. FibroGen has a 1 year low of $0.33 and a 1 year high of $20.90.
FibroGen (NASDAQ:FGEN - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The firm had revenue of $27.14 million for the quarter, compared to analyst estimates of $40.00 million.
Hedge Funds Weigh In On FibroGen
A number of institutional investors and hedge funds have recently modified their holdings of FGEN. Altshuler Shaham Ltd acquired a new stake in FibroGen during the 4th quarter worth $28,000. Royal Bank of Canada lifted its holdings in shares of FibroGen by 45.3% in the 3rd quarter. Royal Bank of Canada now owns 2,314 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 721 shares during the last quarter. Dark Forest Capital Management LP purchased a new stake in shares of FibroGen in the 1st quarter valued at about $47,000. Tower Research Capital LLC TRC boosted its position in shares of FibroGen by 231.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,385 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 2,363 shares during the period. Finally, Quantbot Technologies LP purchased a new position in FibroGen during the 2nd quarter worth approximately $39,000. Institutional investors and hedge funds own 72.71% of the company's stock.
Insider Activity at FibroGen
In other news, CEO Thane Wettig bought 50,000 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was bought at an average cost of $1.91 per share, for a total transaction of $95,500.00. Following the acquisition, the chief executive officer now directly owns 470,178 shares of the company's stock, valued at approximately $898,039.98. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.39% of the company's stock.
About FibroGen
(
Get Free Report)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Featured Stories
Before you consider FibroGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroGen wasn't on the list.
While FibroGen currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
